We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.05%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
26
DELISTED
Cymabay Therapeutics
CBAY
$50.9M 0.43%
3,917,700
+925,925
+31% +$11.5M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.57B
$40.8M 0.35%
2,049,020
– –
NVTA
28
DELISTED
Invitae Corporation
NVTA
$39.4M 0.33%
8,399,411
+1,111,111
+15% +$7.93M
BLUE
29
DELISTED
bluebird bio
BLUE
$34.1M 0.29%
15,440
– –
ABEO icon
30
Abeona Therapeutics
ABEO
$348M
$31.3M 0.27%
87,375
+8,000
+10% +$2.97M
HALO icon
31
Halozyme
HALO
$12.3B
$31M 0.26%
1,581,424
– –
SGMO
32
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$30.5M 0.26%
1,607,579
-505,797
-24% -$10.8M
NKTR icon
33
Nektar Therapeutics
NKTR
$2.53B
$29.3M 0.25%
18,360
+6,898
+60% +$8.89M
BLCM
34
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$27.2M 0.23%
415,158
-88,073
-18% -$6.65M
YARW
35
Yarrow Bioscience
YARW
$97.2M
$26.3M 0.22%
+194
New +$23.6M
XNCR icon
36
Xencor
XNCR
$2.07B
$26.1M 0.22%
872,072
– –
LKFT
37
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$25.9M 0.22%
259,894
– –
EXEL icon
38
Exelixis
EXEL
$13.4B
$25.8M 0.22%
1,162,644
-343,855
-23% -$9.5M
GWPH
39
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$25M 0.21%
221,800
– –
MRUS
40
DELISTED
Merus
MRUS
$21.5M 0.18%
1,160,014
– –
AIMT
41
DELISTED
Aimmune Therapeutics
AIMT
$21.4M 0.18%
673,908
– –
ECYT
42
DELISTED
Endocyte, Inc. Common Stock
ECYT
$20.7M 0.18%
2,277,799
+1,190,476
+109% +$6.57M
NTLA icon
43
Intellia Therapeutics
NTLA
$1.8B
$17.6M 0.15%
833,795
-311,658
-27% -$7.66M
PGNX
44
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$17.2M 0.15%
2,306,184
-844,624
-27% -$5.62M
INSM icon
45
Insmed
INSM
$27.5B
$15.8M 0.13%
700,000
– –
MYOK
46
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$14.2M 0.12%
290,264
-65,000
-18% -$3.38M
BOLD
47
DELISTED
Audentes Therapeutics, Inc
BOLD
$11.8M 0.1%
+393,222
New +$13.3M
QURE icon
48
uniQure
QURE
$3.36B
$11.8M 0.1%
500,000
+17,443
+4% +$380K
AERI
49
DELISTED
Aerie Pharmaceuticals
AERI
$11.7M 0.1%
215,655
-83,701
-28% -$4.68M
CFRX
50
DELISTED
ContraFect Corporation
CFRX
$11.6M 0.1%
8,941
– –
1
2
3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2018 Portfolio in Review

As of Q1 2018, Julian Baker held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Julian Baker deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was Yarrow Bioscience: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Julian Baker's largest Q1 2018 buy was Yarrow Bioscience: 194 shares worth $26.3M.
  • Julian Baker added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Julian Baker's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Julian Baker fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Julian Baker's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Julian Baker opened 5 new positions and closed 13 in Q1 2018.
  • Julian Baker's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.